Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626626 · ClinicalTrials.gov registry record · Phase 1
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00626626: Clinical Trial Phase 1 study, sponsored by Milton S. Hershey Medical Center.
NCT00626626 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00626626, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporation into a regimen for pre-transplant conditioning of acute leukemia and lymphoma patients is logical, exploiting both the anti-tumor activities it is recognized to have and the immunosuppressive activity seen with drugs in its class.
Primary Outcome
Establish the safety of Clofarabine and cyclophosphamide preceding allogeneic hematopoietic engraftment. Assess the efficacy of Clofarabine and cyclophosphamide as conditioning for promoting allogeneic hematopoietic engraftment. Adequacy of engraftment will be assessed via assessment of chimerism (percent donor engraftment). Less than 20% engraftment by day 30 is then failure of engraftment. Safety is defined per common toxicity criteria - Non-Hematological and non renal toxicities of ≥grade 3
Interventions
- DRUG Clofar, Cyclophos, Alemtuzumab
- DRUG Clofar, Cyclophos,Alemtuzumab(Ph II)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Why NCT00626626 stopped before completion
NCT00626626 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Clofar, Cyclophos, Alemtuzumab is the first listed.
NCT00626626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00626626 about?
NCT00626626 is a clinical study titled "Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation". Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporatio...
What is the current status of trial NCT00626626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00626626?
The interventions under investigation include: Clofar, Cyclophos, Alemtuzumab (DRUG), Clofar, Cyclophos,Alemtuzumab(Ph II) (DRUG).
Who is sponsoring clinical trial NCT00626626?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00626626's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia